{‘She lacks zero qualifications’: the US healthcare community prepares for Dr. Høeg's appointment at the FDA.

While America proceeds with historic revisions to its immunization schedules, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by casting doubt on COVID-19 shots throughout the pandemic and has zeroed in on alleged fatalities following COVID-19 vaccination in her short position at the FDA.

Proposed Changes to Childhood Immunization Schedule

Health officials had intended to unveil sweeping changes to the childhood immunization program recently, synchronizing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of alignment with a large portion of the global community with insufficient data for benefit. This reveal has been pushed back until the coming year.

Rather than Vinay Prasad, Høeg is listed to address the audience at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this calendar year.

A New Direction at the Agency

The acting appointment may indicate a strengthened alliance between the drug and biologics divisions as Høeg and Prasad consolidate power at the agency – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

The new acting director has repeatedly called for ending specific childhood vaccine recommendations in the US to become more similar to Denmark, a country with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccination policy – usually the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no obvious experience in medication creation, oversight or leadership, which has been customary for former directors of the biologics center. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a large organization. She is not an expert in pharmaceutical oversight.”

Former commissioners of the center would “grasp laws and regulations and the research of drug development”, said Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who headed CBER have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the new drug program, but the off-patent medication office approves thousands of generic medications. There’s a biologic copycat branch, OTC medication office and other areas, and each of these have to be managed,” Woodcock said. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial administrative component to the position, which manages in excess of 5,000 staff members. “It is a huge administrative position, if you do it right,” the former official said.

Agency Reaction and Disputed Policies

When asked about questions about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on immunizations, a representative responded that the “questions rely on incorrect presumptions”.

“This background is consistent with the functions of her job,” the spokesperson stated, citing the months Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg inherits the agency head's controversial fast-track approval initiative, a controversial one-day drug-approval program that apparently worried her preceding directors. “How are these medications being selected for this expedited pathway? Who takes the choices?” Dr. Howard questioned. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he remarked, “the agency looks to be trending towards more relaxed regulations of pharmaceuticals, except for immunizations.”

Documented History on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, past, critics observe. She released a research paper using unverified crowd-sourced reports to assess the incidence of myocarditis following Covid vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccines are riskier than they are.

Included in her “policy goals” for the new federal leadership featured altering regulations for novel immunizations and ending “optional” vaccines, she said following the vote on a audio program. At the agency, Høeg has according to sources floated the idea of preventing adolescent males from receiving Covid vaccinations.

“She’s an all-around true believer who starts off with her conclusions and works backwards to retrofit the science in a highly disingenuous, dishonest manner,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|